The Latest Cardiac and Vascular News
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has […]
LIVMOR to Develop HeartBeam Branded Version of the FDA Registered LIVMOR Halo+ Portal SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a partnership agreement with LIVMOR Inc., a digital health […]
Phase 2a clinical trial evaluating REG-101 for PAD expected to initiate second half of 2022 ROCKVILLE, Md.–(BUSINESS WIRE)–Regio Biosciences (Regio), a Hibiscus BioVentures company, announced today it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol transport (RCT). Regio expects to initiate a […]
Increasing Low End of Guidance: $1,025 Million – $1,030 Million, up 21% – 22% DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021. Q3 financial summary and operational highlights: Revenue for the quarter totaled […]
Fourth-Quarter and Full-Year Results Reflect Continued Strong Business Momentum and Operational Strength Fourth-Quarter 2021 Worldwide Sales From Continuing Operations Were $13.5 Billion, an Increase of 24% From Fourth-Quarter 2020; Excluding the Impact From Foreign Exchange, Sales Grew 23%; Includes $952 Million of Molnupiravir Sales Fourth-Quarter 2021 GAAP EPS From Continuing […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 million, an increase of 3% […]
Clinicians indicate both Holter and MCT usage expected to grow in 2022 despite their differences CAMPBELL, Calif., Feb. 2, 2022 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, today announced the results of a company survey focused on clinicians’ use of Holter monitors versus mobile cardiac telemetry (MCT). The survey results […]
VANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the […]
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr. Eric Rose as the Company’s Chief Medical Officer (CMO). Dr. Rose has been a non-executive director of Mesoblast since 2013. In […]
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2022 it granted stock options to purchase an aggregate of 200,700 shares of common stock to 15 new employees, whose employment commenced in January 2022, as a material inducement to […]
